Shares of DexCom, Inc. (NASDAQ:DXCM - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-two analysts that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $98.50.
Several equities research analysts recently weighed in on DXCM shares. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Canaccord Genuity Group increased their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Robert W. Baird lowered their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Citigroup restated a "buy" rating and issued a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Barclays boosted their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th.
View Our Latest Stock Analysis on DexCom
DexCom Stock Performance
NASDAQ DXCM remained flat at $83.58 during trading on Wednesday. 2,867,001 shares of the company's stock traded hands, compared to its average volume of 4,013,625. The stock has a 50 day simple moving average of $82.47 and a two-hundred day simple moving average of $79.69. The firm has a market capitalization of $32.77 billion, a P/E ratio of 62.37, a price-to-earnings-growth ratio of 1.86 and a beta of 1.44. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. DexCom has a 1-year low of $57.52 and a 1-year high of $117.19.
DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the business earned $0.32 earnings per share. The business's quarterly revenue was up 12.5% on a year-over-year basis. As a group, equities analysts anticipate that DexCom will post 2.03 EPS for the current year.
Insider Transactions at DexCom
In other news, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director owned 33,411 shares of the company's stock, valued at $2,766,430.80. This represents a 9.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the transaction, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. The trade was a 4.63% decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,190 shares of company stock valued at $2,281,732 over the last 90 days. 0.32% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Private Trust Co. NA lifted its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Golden State Wealth Management LLC lifted its position in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of DexCom during the 1st quarter valued at about $27,000. Optiver Holding B.V. bought a new position in shares of DexCom during the 4th quarter valued at approximately $33,000. Finally, TD Private Client Wealth LLC increased its holdings in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.
DexCom Company Profile
(
Get Free ReportDexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles

Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.